EMulate Therapeutics Publishes Pre-Clinical Mouse Model Showing Immune Checkpoint Receptor Knock-Down in Glioblastoma

EMulate Therapeutics, Inc., a company based in Bellevue, Washington, has announced that its manuscript, titled "Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice," has been accepted for publication by the Open Journal of Biophysics. This study supports previous findings in an animal model of Glioblastoma Multiforme (GBM), a rare and currently untreatable brain glioma. The study highlights the potential of EMulate’s A2 signal treatment, which targets immune checkpoint inhibitors CTLA-4 and PD-1 to reduce tumor growth in GBM.

The study's results align with outcomes from a Phase I clinical trial (NCT02507102), which demonstrated the safety and potential efficacy of the A2 signal treatment in human GBM patients. Xavier Figueroa, Ph.D., Senior Vice President of Pre-Clinical Development at EMulate, emphasized the promise of their radio frequency energy technology (RFE) in treating cancers and other challenging diseases with high unmet medical needs.

EMulate Therapeutics is a clinical-stage company that uses proprietary RFE technology targeting low and ultra-low frequencies to provide therapeutic benefits. The company's technology has shown encouraging results in human clinical trials involving glioblastoma and diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). They are planning Phase III studies for these indications using their A1A treatment signal, which emulates the mechanism of action of the chemotherapy agent paclitaxel. EMulate has also applied to the FDA for approval to treat U.S. patients with DMG under the humanitarian device exemption (HDE) pathway.

In addition to cancer treatments, EMulate has conducted promising preclinical studies in pain management and mental health and is preparing for initial human clinical trials in these areas. The company has also seen positive results in animal health studies, with success in treating over 20 different solid tumor types in canines. Furthermore, the technology has shown benefits in bio-agriculture models.

EMulate Therapeutics licenses its proprietary technology to Hapbee Technologies, Inc., a commercial-stage consumer wellness wearable technology company that spun out from EMulate in 2019. EMulate remains the largest shareholder in Hapbee and receives quarterly royalties from net sales.

The non-sterile, non-invasive, battery-powered medical device developed by EMulate uses low to ultra-low level frequencies to create specific electromagnetic fields that produce biological effects. This includes increasing tubulin polymerization in cancer models, emulating the effects of psychedelic drugs in mental health models, and reducing pain sensations. The device emits a low power magnetic field that can be applied locally or globally, depending on the therapeutic effect needed. The signals are stored as WAV files on the device and emitted via a cable to an attached antenna unit.